Back to top
more

Ophthotech Corporation (OPHT)

(Delayed Data from NSDQ)

$1.39 USD

1.39
303,859

0.00 (0.00%)

Updated Apr 16, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ophthotech Gets Rights to Gene Therapy for BEST Disease

by Zacks Equity Research

Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.

Indrajit Bandyopadhyay headshot

4 Gene Therapy Players Likely to Become Buyout Targets in 2019

by Indrajit Bandyopadhyay

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

Ophthotech (OPHT) Down 2.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ophthotech (OPHT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Top Ranked Momentum Stocks to Buy for March 7th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 7th

    Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus

    by Zacks Equity Research

    Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.

    Ophthotech (OPHT) Down 21.7% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Ophthotech (OPHT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Ophthotech (OPHT) Q3 Earnings Beat, Gene Therapy in Focus

    by Zacks Equity Research

    Ophthotech reports narrower-than-expected loss in the third quarter. It boosts gene therapy pipeline through new agreement and acquisition.

    Why Is Ophthotech (OPHT) Up 5.8% Since Last Earnings Report?

    by Zacks Equity Research

    Ophthotech (OPHT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track

      by Zacks Equity Research

      Ophthotech reports narrower-than-expected loss in the second quarter.

        Ophthotech (OPHT) Soars: Stock Adds 10.4% in Session

        by Zacks Equity Research

        Ophthotech (OPHT) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

          Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus

          by Zacks Equity Research

          Ophthotech (OPHT) reports narrower year-over-year loss for the first quarter.

            Regeneron Eylea Hits 24-Week Primary Endpoint in Study

            by Zacks Equity Research

            Regeneron (REGN) announces encouraging top-line results from the phase III study evaluating Eylea injection in moderately severe to severe non-proliferative diabetic retinopathy.

              Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus

              by Zacks Equity Research

              Ophthotech (OPHT) reports better-than-expected fourth-quarter earnings but misses on sales. The company plans to use novel gene therapy to develop new treatments for ocular diseases.

                Ophthotech Begins Phase II Zimura Study in Stargardt Disease

                by Zacks Equity Research

                Ophthotech (OPHT) is focusing on Zimura following the failure of the Fovista studies.

                  Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set

                  by Zacks Equity Research

                  Regeneron (REGN) announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for Eylea with an action date of Aug 11, 2018.

                    Ophthotech (OPHT) Up 7.1% Since Earnings Report: Can It Continue?

                    by Zacks Equity Research

                    Ophthotech (OPHT) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Regeneron's Stock Falls as Mid-Stage Eye Disease Studies Fail

                      by Zacks Equity Research

                      Regeneron Pharmaceuticals (REGN) announced that it will not advance two mid-stage studies evaluating the combination of nesvacumab of Eylea to phase III.

                        Ophthotech (OPHT) Jumps: Stock Rises 11.9%

                        by Zacks Equity Research

                        Ophthotech Corporation (OPHT) saw its shares rise nearly 12% on the day.

                          Vertex Gets CHMP Recommendation for Orkambi Label Expansion

                          by Zacks Equity Research

                          Vertex (VRTX) received CHMP recommendation for label expansion of Orkambi in children aged 6 to 11 years with CF who have two copies of the F508del mutation.

                            Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus

                            by Zacks Equity Research

                            Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.

                              Roche's Ophthalmology Drug Fails to Meet Primary Endpoint

                              by Zacks Equity Research

                              Roche's (RHHBY) share price declined after its ophthalmology candidate, lampalizumab, failed to meet the primary endpoint in phase III Spectri study.

                                Why Is Ophthotech (OPHT) Up 7.4% Since the Last Earnings Report?

                                by Zacks Equity Research

                                Ophthotech (OPHT) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  Ophthotech's Fovista Combo Regimen Disappoints in Phase III

                                  by Zacks Equity Research

                                  Ophthotech (OPHT) disappoints with poor evaluation of Fovista combined with Eylea or Avastin for treatment of AMD in phase III. The study misses the primary endpoint.

                                    AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected

                                    by Zacks Equity Research

                                    AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.

                                      Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura

                                      by Zacks Equity Research

                                      Ophthotech Corporation (OPHT) reported narrower-than-expected loss in the second quarter and also beat sales expectations.